(Q28371015)

English

KRAS G13D

genetic variant

GLY13ASP
RS112445441

In more languages

default for all languages

No label defined

No description defined

Statements

missense mutation

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/81

human chromosome 12

genomic assembly

Genome assembly GRCh37

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/81

25398281

genomic assembly

Genome assembly GRCh37

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/81

25398281

genomic assembly

Genome assembly GRCh37

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/81

biological variant of

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/81

positive therapeutic predictor for

determination method or standard

CIViC evidence level D

CIViC 4-star trust rating

medical condition treated

colorectal cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/145

Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab

determination method or standard

CIViC evidence level B

CIViC 4-star trust rating

medical condition treated

colorectal cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/306

Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab

negative therapeutic predictor for

medical condition treated

colorectal cancer

statement disputed by

Cetuximab treatment for metastatic colorectal cancer with KRAS p.G13D mutations improves progression-free survival

determination method or standard

CIViC evidence level B

CIViC 2-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/806

Cetuximab treatment for metastatic colorectal cancer with KRAS p.G13D mutations improves progression-free survival

determination method or standard

CIViC evidence level B

CIViC 4-star trust rating

medical condition treated

colorectal cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1181

Meta-analysis comparing the efficacy of anti-EGFR monoclonal antibody therapy between KRAS G13D and other KRAS mutant metastatic colorectal cancer tumours.

determination method or standard

CIViC evidence level C

CIViC 2-star trust rating

medical condition treated

colorectal cancer

statement disputed by

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/6320

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies

determination method or standard

CIViC evidence level C

CIViC 2-star trust rating

medical condition treated

colorectal cancer

statement disputed by

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/6320

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies

determination method or standard

CIViC evidence level C

CIViC 2-star trust rating

medical condition treated

colorectal cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/6322

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies

determination method or standard

CIViC evidence level C

CIViC 2-star trust rating

medical condition treated

colorectal cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/6322

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies

determination method or standard

CIViC evidence level D

CIViC 1-star trust rating

medical condition treated

colorectal cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/3889

KRAS exon 2 mutations influence activity of regorafenib in an SW48-based disease model of colorectal cancer

determination method or standard

CIViC evidence level C

CIViC 3-star trust rating

medical condition treated

colorectal cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/2178

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

determination method or standard

CIViC evidence level D

CIViC 4-star trust rating

medical condition treated

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/2041

Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models

Identifiers

CIViC variant ID

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/81

dbSNP Reference SNP number

1 reference

HGVS nomenclature

NM_033360.3:c.38G>A

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/81

NP_004976.2:p.Gly13Asp

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/81

NC_000012.11:g.25398281C>T

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/81

ENST00000256078.4:c.38G>A

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/81

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28371015&oldid=2014798318"